EIKN Eikon Therapeutics, Inc.
Price Chart
Executive Summary
Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing a 63.1% ORR and 90.8% DCR across 65 evaluable patients, with a manageable safety profile supporting outpatient administration. Initial Phase 1/2 data for EIK1003 (PARP1 inhibitor) showed a 24.5% ORR in combination with paclitaxel in heavily pretreated patients, though the stock has historically declined ~12% on prior neutral filings, suggesting limited market enthusiasm for early-stage data without a clear regulatory catalyst.
Actionable Insight
The data are encouraging but early-stage and non-registrational; no PDUFA or pivotal trial readout is imminent. Traders should watch for initiation of Phase 3 trials for EIK1001 (TeLuRide-008) and any partnership or financing announcements. The stock's historical negative drift on prior neutral filings suggests limited near-term upside from these data alone.
Key Facts
- EIK1001 (TeLuRide-005) Phase 2: 63.1% ORR and 90.8% DCR in 65 evaluable first-line NSCLC patients (non-squamous and squamous cohorts).
- EIK1001 safety profile: most TEAEs Grade 1-2; Grade 3+ TRAEs included neutropenia (30.6%), anemia (9.7%), thrombocytopenia (9.7%); all CRS events Grade 1-2.
- EIK1003 (Phase 1/2) monotherapy: 14.3% ORR overall, 26.7% in PARP-naïve patients; median DOR 7.8 months in 5 confirmed responders.
- EIK1003 + paclitaxel (Cohort 1C): 24.5% ORR in 53 evaluable patients (29.6% in platinum-resistant ovarian, 19.2% in breast cancer); 92% of responders had prior taxane therapy.
- No financial data (revenue, EPS, guidance) reported in this press release.
- Company is a late-stage clinical biopharma with no approved products; market cap ~$587M.
Financial Impact
No financial data provided; clinical data updates only.
Risk Factors
- EIK1001 and EIK1003 are investigational and may fail in later-stage trials.
- No revenue or approved products; company requires substantial additional funding.
- Competitive landscape: multiple TLR agonists and PARP inhibitors in development.
- Historical stock performance shows negative drift on prior neutral filings (~12% at T+20).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303899 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
8-K
| $8.35 awaiting T+5 | awaiting T+5 | — | $8.75 (+4.79%) |
|
Jun 1, 2026
11d ago
|
8-K
| $10.79 $8.96 | ▼ −16.96% | ▼ −14.21% | $8.75 (−18.91%) |
|
May 30, 2026
13d ago
|
Press Release
| $10.79 $8.96 | ▼ −16.96% | ▼ −14.21% | $8.75 (−18.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access